Many of you repeatedly in my mail have asked for paid calls and what they will be and all.Now as an amateur and being a social guy I would always safeguard the vested interest of investors than something else.The open blog is a place for me to give guidance..paid blog is for the one who needs those calls and my bigtime guidance desperately.Anyways here"s an example of a paid member call and the type which I provided just few days back.
Sunday, April 4, 2010
Market outlook and stock idea:-IOL Chemicals & Pharmaceuticals Ltd
Scripscan:IOL Chemicals & Pharmaceuticals Ltd
Traded in:Nse-bse
cmp:60
Target:72
Percentage:20%
Duration:3-4 months
Long term target:100(6-10 months)
Story:Established in 1986, IOLCP, a public-listed company (BSE), is one of the largest manufacturers of APIs and speciality chemicals with presence in over 52 countries across the world, IOLCP manufactures and supplies APIs and speciality chemicals for use in various pharmaceutical, Textile, Packaging, Lamination, Pesticides, Food processing applications. Its product portfolio includes APIs, lbuprofen, speciality chemicals such as ethyl acetate, acetic anhydride, Lso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride and bulk chemicals such as Glacial Acetic acid. IOLCP is currently in a phase of expansion with an investment outlay of Rs. 256 crore which would include capacity expansion for its various product lines, forward and backward integration and increase in cogeneration of power. IOLCPs overseas customers are spread out across several countries including Argentina, Brazil, China, Denmark, Germany, Singapore, Hong Kong, Kenya, Malaysia, Peru, Egypt and many others. The company has strong business relationships with a number of prestigious clients such as Ranbaxy Labs, Aurobindo Pharma, Dr Reddy, DS Group, CIPLA, Uflex Industries, ITC Limited, ICI Paints, Asian Paints, Pidilite, Rallis India, Hindustan Polymide, Gujarat Super Phoshhate, Avon Organics Ltd. etc.Company has reported excellent results for Q3 with PAT of 6.38 crs. as against 86 lakhs in corresponding quarters of previous year. Company has recently commenced manufacturing operations at its new Plant of IBB with capacity of 6600 TPA which is R/M for its Pharma Product 'Ibuprofen.IOL is second company in India to produce IBB.Production capacity of Ibuprofen has also been increased to 3600 TPA.IOL has also started production of MCA with 7200 TPA capacity and Acetyl Chloride with 5200 TPA capacity. These are also R/M for Ibuprofen.With completion of backward integration and expansion (as company has cogen power also), IOL is emerging as an efficient chemical-cum-pharma company in India and should report excellent results in coming quarters.At present prices of 60 its quoting at just 5 times its forward earnings.I feel the downsides at present levels are capped and it may certainly surprise one on the upside front.An excellent buy in chemical industry.
Regards,
ARUN
9804589299
I can be reached at:arunanalyst@rediffmail.com
Sunday, April 4, 2010
Market outlook and stock idea:-IOL Chemicals & Pharmaceuticals Ltd
Scripscan:IOL Chemicals & Pharmaceuticals Ltd
Traded in:Nse-bse
cmp:60
Target:72
Percentage:20%
Duration:3-4 months
Long term target:100(6-10 months)
Story:Established in 1986, IOLCP, a public-listed company (BSE), is one of the largest manufacturers of APIs and speciality chemicals with presence in over 52 countries across the world, IOLCP manufactures and supplies APIs and speciality chemicals for use in various pharmaceutical, Textile, Packaging, Lamination, Pesticides, Food processing applications. Its product portfolio includes APIs, lbuprofen, speciality chemicals such as ethyl acetate, acetic anhydride, Lso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride and bulk chemicals such as Glacial Acetic acid. IOLCP is currently in a phase of expansion with an investment outlay of Rs. 256 crore which would include capacity expansion for its various product lines, forward and backward integration and increase in cogeneration of power. IOLCPs overseas customers are spread out across several countries including Argentina, Brazil, China, Denmark, Germany, Singapore, Hong Kong, Kenya, Malaysia, Peru, Egypt and many others. The company has strong business relationships with a number of prestigious clients such as Ranbaxy Labs, Aurobindo Pharma, Dr Reddy, DS Group, CIPLA, Uflex Industries, ITC Limited, ICI Paints, Asian Paints, Pidilite, Rallis India, Hindustan Polymide, Gujarat Super Phoshhate, Avon Organics Ltd. etc.Company has reported excellent results for Q3 with PAT of 6.38 crs. as against 86 lakhs in corresponding quarters of previous year. Company has recently commenced manufacturing operations at its new Plant of IBB with capacity of 6600 TPA which is R/M for its Pharma Product 'Ibuprofen.IOL is second company in India to produce IBB.Production capacity of Ibuprofen has also been increased to 3600 TPA.IOL has also started production of MCA with 7200 TPA capacity and Acetyl Chloride with 5200 TPA capacity. These are also R/M for Ibuprofen.With completion of backward integration and expansion (as company has cogen power also), IOL is emerging as an efficient chemical-cum-pharma company in India and should report excellent results in coming quarters.At present prices of 60 its quoting at just 5 times its forward earnings.I feel the downsides at present levels are capped and it may certainly surprise one on the upside front.An excellent buy in chemical industry.
Regards,
ARUN
9804589299
I can be reached at:arunanalyst@rediffmail.com
